Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| RSV Therapeutics LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.
A double-blind, randomized, placebo-controlled, comparative multicenter study in two groups. A total of 120 patients with uncomplicated influenza or other acute respiratory viral infections are planned to be randomized. Patients will be randomized into 2 groups: 60 patients in the treatment group 200 mg XC221 and 60 patients in the placebo group. The purpose of the clinical trial is to assess the safety, tolerability and efficacy of the drug XC21 in treatment of influenza or other acute respiratory viral infections. The primary objective is to demonstrate the difference between the groups in the time of the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale. The study will consist of the following periods: screening (duration not more than 36 hours from the moment of the first symptoms of the disease), treatment period (3 days), follow-up period (11 ± 1 days after completion of treatment with the study drug/placebo). The duration of participation in the study for each patient is no more than 16 days and 12 hours.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| XC221 | Experimental | XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period |
|
| Placebo | Placebo Comparator | Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| XC221 | Drug | Participants will receive 200 mg XC221 once a day during 3 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Time to sustained improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. | The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| Measure | Description | Time Frame |
|---|---|---|
| The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms (0 points). | The time of the first assessment of 3 consecutive ratings on the Modified Jackson Scale, in which all the clinical symptoms were 0 points. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. |
| Measure | Description | Time Frame |
|---|---|---|
| The average concentration of MxA protein in the blood at Visit 1, Visit 4 and at Visit 6. | From Day 1 up to Day 6 | |
| Changes in the concentration of MxA protein in the blood at Visit 4 and at Visit 6 compared to Visit 1. | From Day 1 up to Day 6 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Federal State Budgetary Institution of Health "Northern Medical Clinical Center named after NA Semashko of the Federal Medical and Biological Agency" | Arkhangelsk | 163000 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 26, 2021 | |
| Reset | Sep 23, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Participants will receive Placebo once a day during 3 days |
|
| From the moment of the first dose up to Day 14 |
| The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. | Total score of no more than 3 points, when there is no more than 1 point for each symptom, measured in hours from the moment of taking the first dose of the drug. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| Time to normalization of body temperature. | Measured in hours. Normalization means the establishment of body temperature below 37° C without a rise above these values in the subsequent observation period. | From the moment of the first dose up to Day 14 |
| The average score according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days. | The average score according to the Modified Jackson Scale on the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| The proportion of patients with a sum of not more than 3 points according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days | Score for each symptom should be no higher than 1 point at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days from the moment of the start of treatment. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| The proportion of patients with the normalization of body temperature on the first - the 14th days from the start of treatment; | From the moment of the first dose up to Day 14 |
| Time to disappearance (0 points) of each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. | Symptom (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) manifested at the level of 2 or 3 points at the first assessment at Visit 0 (Day 0). Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| The proportion of patients with 0 points score for each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. | Modified Jackson Scale (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) at the 2nd, 3rd 2nd, 4th, 5th, 6th, 7th and 8th days from the moment of the start of treatment in a population of patients with the corresponding symptom shown at the level of 2 or 3 points at Visit 0 (Day 0). Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| The proportion of patients with a detected viral pathogen | The proportion of patients with a detected viral pathogen at Visit 0, Visit 4 and Visit 6. | From the moment of the first dose up to Day 14 |
| The proportion of patients with a detected viral pathogen at Visit 4 and Visit 6 compared with the initial proportion of such patients in the XC221. | From the moment of the first dose up to Day 14 |
| The frequency of adverse events (AEs) and serious adverse events (SAEs) in the XC221 treatment group and in the placebo group. | From the moment of the first dose up to Day 14 |
| The average concentration of C-reactive protein in the blood at Visit 1, Visit 4 and Visit 6. | From Day 1 up to Day 6 |
| Changes in the concentration of C-reactive protein in the blood at Visit 4 and Visit 6 compared to Visit 1. | From Day 1 up to Day 6 |
| The average concentration of cytokines at Visit 1, Visit 4 and at Visit 6. | The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in blood at Visit 1, Visit 4 and at Visit 6. | From Day 1 up to Day 6 |
| The percentage change in the concentration of cytokines at Visit 4 and at Visit 6 compared with Visit 1. | The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN -γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3 , MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in blood at Visit 4 and Visit 6 compared with Visit 1. | From Day 1 up to Day 6 |
| Correlation between the concentration of cytokines/chemokines and the assessment of the Modified Jackson scale for measuring respiratory symptoms (in dynamics). | Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. | From the moment of the first dose up to Day 14 |
| The average concentration of cytokines in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6 | The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6. | From Day 1 up to Day 6 |
| The percentage change in the concentration of cytokines in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1. | The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1. | From Day 1 up to Day 6 |
| Regional State Budgetary Institution of Health "Belgorod Regional Clinical Hospital of St. Joasaph" | Belgorod | 308007 | Russia |
| City Clinical Hospital №9 | Izhevsk | 426063 | Russia |
| Kuban State Medical University | Krasnodar | 350063 | Russia |
| State budget institution of health care of the Moscow region "Krasnogorsk city hospital number 1" | Krasnogorsk | 143408 | Russia |
| Non-governmental Healthcare Institution "N.A.Semashko Road Clinical Hospital at the Lyublino station of the open joint-stock company "Russian Railways" | Moscow | 109386 | Russia |
| Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after Academician I.P. Pavlova" of the Ministry of Health of the Russian Federation | Ryazan | 390026 | Russia |
| Ryazan State Medical University n.a. Pavlov | Ryazan | 390026 | Russia |
| The Center for Prevention and Fight about AIDS and Infectious Diseases | Saint Petersburg | 190103 | Russia |
| LLC "Aurora Medi" | Saint Petersburg | 193232 | Russia |
| The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation | Saint Petersburg | 197110 | Russia |
| Research Institute of Influenza | Saint Petersburg | 197376 | Russia |
| City Clinical Hospital №40 of Kurortny District | Saint Petersburg | 197706 | Russia |
| LLC "Astarta" | Saint Petersburg | 199226 | Russia |
| Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Health of the Russian Federation | Yaroslavl | 150000 | Russia |
| State Budgetary Healthcare Institution (SBHI) of Yaroslavl region | Yaroslavl | 150007 | Russia |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 26, 2021 | Sep 23, 2021 |
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718222 | XC221 |
Not provided
Not provided
Not provided